XML 28 R10.htm IDEA: XBRL DOCUMENT v2.3.0.15
Convertible Preferred Stock Investment
9 Months Ended
Sep. 30, 2011
Investments, All Other Investments [Abstract] 
Cost-method Investments, Description [Text Block]
Note 4.
Convertible Preferred Stock Investment
 
As of September 30, 2011 and December 31, 2010 the Company has a $2,617,000 investment in the convertible preferred stock (“Preferred Stock”) of Mevion Medical Systems, Inc (“Mevion”), formerly Still River Systems, Inc., representing an approximate 1.5% interest in Mevion.  The Company accounts for this investment under the cost method.
 
The Preferred Stock is convertible at any time at the option of the holder into shares of common stock of Mevion at a conversion price, subject to certain adjustments, but initially set at the original purchase price.  The Preferred Stock has voting rights equivalent to the number of common stock shares into which it is convertible, and holders of the Preferred Stock, subject to certain exceptions, have a pro-rata right to participate in subsequent stock offerings.  In the event of liquidation, dissolution, or winding up of Mevion, the Preferred Stock holders have preference to the holders of common stock, and any other class or series of stock that is junior to the Preferred Stock.  The Company does not have the right to appoint a member of the Board of Directors of Mevion.
 
The Company carries its investment in Mevion at cost and reviews it for impairment on a quarterly basis, or as events or circumstances might indicate that the carrying value of the investment may not be recoverable.  The Company evaluated this investment for impairment at December 31, 2010 and reviewed it at September 30, 2011 in light of both current market conditions and the ongoing needs of Mevion to raise cash to continue its development of the first compact, single room PBRT system.  Based on its analysis, the Company estimates that there is currently an unrealized loss (impairment) of approximately $1.5 million.
 
In assessing whether the impairment is other than temporary, we evaluated the length of time and extent to which market value has been below cost, the financial condition and near term prospects of Mevion and our ability and intent to retain our investment for a period sufficient to allow for an anticipated recovery in the market value.  Although the investment is not without certain risk, and the manufacture of the first unit has taken longer than originally anticipated, the Company believes that the current market value is a temporary situation brought on solely due to the continuing downturn of the economy, and is not a reflection on the progress or viability of Mevion or its PBRT design.  Based on the continuing progress being made by Mevion toward the manufacture and installation of the first single room PBRT system, the Company believes that our investment in Mevion is not other than temporarily impaired.